Respira Therapeutics, Inc.
Respira Therapeutics, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Respira Therapeutics, Inc..
Respira Therapeutics, Inc. is a company.
Key people at Respira Therapeutics, Inc..
Key people at Respira Therapeutics, Inc..
Respira Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative inhaled therapies for cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).[1][2][5][7] Its lead product, RT234 (vardenafil inhalation powder), is a first-in-class, as-needed (PRN) treatment designed for rapid relief of symptoms like breathlessness and fatigue, using advanced particle engineering and proprietary dry powder inhaler (DPI) technology to deliver drugs deeper into the lungs—three to four times more effectively than standard inhalers.[2][3][5][7] The company serves PH patients underserved by chronic therapies, addressing acute exertional symptoms that disrupt daily life, with RT234 currently advancing through Phase 2 trials and backed by under $5 million in funding.[2][5]
Founded around 2010-2011 with seed funding from Cottonwood Technology Fund, Respira began as an early-stage product development company in Santa Fe, NM, and Austin, TX, focusing on pulmonary delivery for respiratory diseases with unmet needs.[3] It achieved proof-of-principle for its DPI drug engine technology (DET), establishing early partnerships with Emergent Technologies and Enavail for dry powder portfolios, and targeting the 505(b)(2) regulatory path for faster approval.[3] Leadership includes CEO John Kollins, with 35 years of experience including co-founding and selling Satsuma Pharmaceuticals (migraine drug-device product), and SVP Raj Kewalramani, expert in drug delivery and manufacturing from roles at Elan and others.[1] By 2025, headquartered in Palo Alto, CA (with prior ties to Albuquerque, NM), Respira progressed to clinical-stage with RT234 and entered an acquisition option agreement with Gossamer Bio.[4][5]
Respira rides the wave of precision inhaled therapies in the $52 billion pulmonary market, targeting small-airway diseases where systemic drugs fail due to poor lung penetration.[3][7] Timing aligns with rising PH prevalence—PAH/PH-ILD affect millions with persistent symptoms despite background therapies—fueled by aging populations and post-COVID respiratory burdens.[2][5] Market forces favor inhalers with better bioavailability and patient-centric PRN models, as current devices underperform in severe cases; Respira's tech influences ecosystems by partnering for commercialization and potentially disrupting via acquisitions like the Gossamer option, accelerating PH innovation.[3][5]
Respira's momentum hinges on RT234's Phase 2 data and the Gossamer acquisition option, potentially fast-tracking commercialization as a PRN PH standard.[5] Evolving trends like AI-optimized formulations and combo-device therapies will shape its path, with influence growing through partnerships if acquired—expanding Gossamer's PH pipeline.[5] This positions Respira to transform acute respiratory relief, building on its DPI edge to meet unmet needs in a high-stakes market.[2][3]
